Glycoprotein IIb/IIIa inhibitors

Jump to navigation Jump to search

WikiDoc Resources for Glycoprotein IIb/IIIa inhibitors

Articles

Most recent articles on Glycoprotein IIb/IIIa inhibitors

Most cited articles on Glycoprotein IIb/IIIa inhibitors

Review articles on Glycoprotein IIb/IIIa inhibitors

Articles on Glycoprotein IIb/IIIa inhibitors in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Glycoprotein IIb/IIIa inhibitors

Images of Glycoprotein IIb/IIIa inhibitors

Photos of Glycoprotein IIb/IIIa inhibitors

Podcasts & MP3s on Glycoprotein IIb/IIIa inhibitors

Videos on Glycoprotein IIb/IIIa inhibitors

Evidence Based Medicine

Cochrane Collaboration on Glycoprotein IIb/IIIa inhibitors

Bandolier on Glycoprotein IIb/IIIa inhibitors

TRIP on Glycoprotein IIb/IIIa inhibitors

Clinical Trials

Ongoing Trials on Glycoprotein IIb/IIIa inhibitors at Clinical Trials.gov

Trial results on Glycoprotein IIb/IIIa inhibitors

Clinical Trials on Glycoprotein IIb/IIIa inhibitors at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Glycoprotein IIb/IIIa inhibitors

NICE Guidance on Glycoprotein IIb/IIIa inhibitors

NHS PRODIGY Guidance

FDA on Glycoprotein IIb/IIIa inhibitors

CDC on Glycoprotein IIb/IIIa inhibitors

Books

Books on Glycoprotein IIb/IIIa inhibitors

News

Glycoprotein IIb/IIIa inhibitors in the news

Be alerted to news on Glycoprotein IIb/IIIa inhibitors

News trends on Glycoprotein IIb/IIIa inhibitors

Commentary

Blogs on Glycoprotein IIb/IIIa inhibitors

Definitions

Definitions of Glycoprotein IIb/IIIa inhibitors

Patient Resources / Community

Patient resources on Glycoprotein IIb/IIIa inhibitors

Discussion groups on Glycoprotein IIb/IIIa inhibitors

Patient Handouts on Glycoprotein IIb/IIIa inhibitors

Directions to Hospitals Treating Glycoprotein IIb/IIIa inhibitors

Risk calculators and risk factors for Glycoprotein IIb/IIIa inhibitors

Healthcare Provider Resources

Symptoms of Glycoprotein IIb/IIIa inhibitors

Causes & Risk Factors for Glycoprotein IIb/IIIa inhibitors

Diagnostic studies for Glycoprotein IIb/IIIa inhibitors

Treatment of Glycoprotein IIb/IIIa inhibitors

Continuing Medical Education (CME)

CME Programs on Glycoprotein IIb/IIIa inhibitors

International

Glycoprotein IIb/IIIa inhibitors en Espanol

Glycoprotein IIb/IIIa inhibitors en Francais

Business

Glycoprotein IIb/IIIa inhibitors in the Marketplace

Patents on Glycoprotein IIb/IIIa inhibitors

Experimental / Informatics

List of terms related to Glycoprotein IIb/IIIa inhibitors

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]

Overview

Glycoprotein IIb/IIIa inhibitors, also GpIIb/IIIa inhibitors, are a class of antiplatelet agents.

Several GpIIb/IIIa inhibitors exist:

Indications

Glycoprotein IIb/IIIa inhibitors are frequently used during percutaneous coronary interventions (angioplasty with or without intracoronary stent placement).

They work by preventing platelet aggregation and thrombus formation. They do so by inhibition of the GpIIb/IIIa receptor on the surface of the platelets. By blocking the GPIIbIIIa receptor, they block the ability of platelets to cross link via fibrinogen.

The agents in this class are administered intravenously. Oral forms of these agents were associated with increased mortality, possibly due to underdosing of the agents.

History

Their development arose from the understanding of Glanzmann's thrombasthenia, a condition in which the GpIIb/IIIa is lacking.[1]

Reference

  1. Seligsohn U. Glanzmann thrombasthenia: a model disease which paved the way to powerful therapeutic agents. Pathophysiol Haemost Thromb. 2002 Sep-Dec;32(5-6):216-7. PMID 13679645. Free Full Text.

Additional Resources



Template:WikiDoc Sources